MedTrace Logo

Assess Efficacy and Safety of Durvalumab Alone or Combined With Bevacizumab in High Risk of Recurrence HCC Patients After Curative Treatment

NCT03847428 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 908

Last updated 2026-03-06

No results posted yet for this study

Summary

A global study to assess the efficacy and safety of durvalumab in combination with bevacizumab or durvalumab alone in patients with hepatocellular carcinoma who are at high risk of recurrence.

Conditions

Interventions

DRUG

Durvalumab

Durvalumab IV (intravenous)

DRUG

Bevacizumab

Bevacizumab IV (intravenous)

OTHER

Placebo

Saline solution for Durvalumab and/or Bevacizumab masking (IV intravenous) or Dextrose for Durvalumab masking

Sponsors & Collaborators

Principal Investigators

  • Jia Fan, PhD · Liver Cancer Institute Zhongshan Hospital, Fudan University

  • Jennifer Knox, MD · Solid Tumor Medical Oncology Princess Margaret Cancer Centre

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
150 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-04-29
Primary Completion
2026-05-29
Completion
2027-05-31
FDA Drug
Yes

Countries

  • United States
  • Australia
  • Austria
  • Brazil
  • Canada
  • China
  • Egypt
  • France
  • Germany
  • Hong Kong
  • India
  • Italy
  • Japan
  • Peru
  • Philippines
  • Poland
  • Puerto Rico
  • Russia
  • Singapore
  • South Korea
  • Taiwan
  • Thailand
  • Turkey (Türkiye)
  • Vietnam

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03847428 on ClinicalTrials.gov